Capitainer AB

Harvard Public Health recently published a post featuring Capitainer, were they talked to Jochen Schwenk, a professor at the KTH Royal Institute of Technology in Stockholm about a new study performed by utilizing the standard postal service and our at-home sampling technology. In the study, the researchers performed proteome profiling of 276 proteins by proximity extension assays (PEA) from Capitainer samples. Read the full article linked below. Reach out to us if you interested in performing simpler, cheaper, and more inclusive health monitoring studies. #proteomics #healthmonitoring #selfsampling https://lnkd.in/eEaTK85K

We are proud to announce that our Chief Medical Officer, Mathias Karlsson, has been elected to the board of Labquality! This recognition reflects Mathias's extensive expertise and commitment, and is also in line with Capitainer's mission to improve healthcare diagnostics worldwide. Labquality focuses on enhancing quality in healthcare, pharmaceuticals, and medical technology through external quality assessments, regulatory advice, clinical investigations, and training. "It is an honor to join Labquality's board. The mission for Labquality aligns with my career-long aspiration to support patients and healthcare providers with new, high-quality solutions. I look forward to contributing to our efforts to promote healthcare quality globally, a goal that resonates with Capitainer's vision of equal access to healthcare diagnostics for all," says Mathias Karlsson. Read the full press release here: https://lnkd.in/dbPHNyrq #MedTech #Diagnostics #PatientCare #QualityHealthcare #HealthcareInnovation

Capitainer is proud to see its blood self-sampling technology featured in leading healthcare publications in Sweden, Norway, and Denmark. The articles, which were published in Dialäsen (Sweden), Dagens Medisin (Norway) and Nefrologisk Tidsskrift (Denmark), highlight a major study carried out in Norway last year, which found that Capitainer’s volumetric dried blood spot sampling device, Capitainer®B, is suitable for routine monitoring of kidney transplant recipients. The Norwegian study was carried out at Oslo University Hospital and University of Oslo and was led by Head of the Clinical Pharmacology Nils Tore Vethe. In Dagens Medisin, he highlights the positive impact that self-sampling can have on patient quality of life. The findings were published in the British Journal of Clinical Pharmacology in an article entitled: ‘Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients’. https://lnkd.in/dXZJWi3z #Nephrology #renaltransplant #transplantation

Capitainer samples were used together with Olink Proteomics technology in a recently published paper using multiplex proteomics approaches with our at-home sampling solutions. This is yet another example of how Capitainer can enable efficient research studies with individual centric sampling approaches. In this the blog article, we provide an overview on the potential of quantitative multiplex proteomics within diagnostics and disease monitoring and look at some of the methodologies in use today. Stay tuned for more news about studies carried out with Capitainer sampling and advanced proteomics analysis. You find the publication mentioned above here: https://lnkd.in/dmaXy989 #proteomics #precisionmedicine #biomarkers https://lnkd.in/dVSVtGzi

Exciting news! Capitainer is proud to support Chalmers University of Technology in the groundbreaking SCAPIS2-HOME study on precision nutrition. Using our Capitainer®B50 self-sampling card, this innovative research aims to uncover how personalized dietary advice can prevent heart attacks and strokes.   Professor Rikard Landberg who is leading the study states, "This is groundbreaking because, for the first time, we will have the opportunity to directly link how different individuals react to meals — also focusing on long-term health outcomes. The advantage of this study is the extensive and sophisticated investigations into heart and vascular health and lung function which will be conducted, to which our meal outcomes can be linked."   Our CEO, Christopher Aulin, emphasizes, "This research demonstrates the potential of self-sampling and Capitainer's blood sampling solution. It offers the opportunity to conduct large scientific studies more efficiently and with the participants in focus. We are very pleased with the collaboration with Chalmers and that our products can contribute to new knowledge and hopefully preventive measures for major public health issues."   Read the full press release here: https://lnkd.in/dQJvUfze   #Capitainer #selfsampling #SCAPIS

Lasec® Group is now our strategic partner for South- and sub-Saharan Africa as we have signed a new distribution agreement. With over 75 years in business to serve the laboratory and scientific community across Africa, Lasec® is a perfect partner to bring Capitainer to this market. The distribution deal includes the registration of Capitainer products with local authorities, thereby giving Capitainer access to the expanding African market. This will simplify logistics for local customers and large foundations operating on the African continent, with whom Capitainer already has established relationships. We are excited and truly look forward to working together and make Capitainer #microsampling products available for research and healthcare purposes. https://lnkd.in/dsQkqJiS #ScienceForAfrica #Selfsampling #Diagnostics

Can Capitainer qDBS technology improve access to gastrointestinal disease diagnostics? Yes, according to Mindy Engevik, Donald Chace, Thomas Horvath, and Santosh Thapa, Ph.D. – a team of researchers from across the US that sought an easier way of analyzing and diagnosing gastrointestinal ailments, dried fecal samples provides promise for the future. We are impressed by their work and creativity to show additional value of the qDBS technology, that enables highly accurate and protected dried matrix samples. Read the linked new interview article with the scientists and get inspired by their vision and the developed work. Reach out to us at Capitainer if you also have innovative ideas for dried sample research and discuss if Capitainer cards could facilitate your research. The Pathologist https://lnkd.in/eBPktUFp

📬 Exciting updates from Capitainer! Our latest newsletter is here, featuring a publication highlight validating our Capitainer®B for drug testing, showcasing new partnerships, and a deep dive into the evolution of blood sampling cards. We also celebrate a significant funding boost aimed at expanding our U.S. operations. Happy reading!   Want to receive the Capitainer newsletter to your e-mail? Sign up here: https://lnkd.in/duCFj87h   #Capitainer #HealthcareInnovation #Microsampling

Interested in at-home sampling for biomarkers of hypothyroidism? Capitainer recently announced our collaboration with Life Genomics with the first of the new tests to be offered focusing on hypothyroidism, a condition characterized by a lack of thyroid hormone, detected by using the TSH and fT4 blood biomarkers. Capitainer will attend #ECE2024, 26th European Congress of Endocrinology, Stockholm Sweden. Meet our specialists John Dinan and Ylva Andell Elias in booth number 10, to learn more about how Capitainer can offer new possibilities for patient centric blood sampling solutions and discuss how to get started with a project for better personalized care. https://lnkd.in/g8mEteXZ #endocrinology #hypothyroidism #microsampling

A recent publication has proven the suitability of testing drugs of abuse and alcohol consumption from one fingerstick blood collection event via Capitainer®. Regardless of where and why testing is performed, the intrusive nature of supervised urine sample collection has sparked a demand for alternative sample types that are more discrete and also amenable to multi-panel testing. The team of researchers from The Karolinska Institutet, Stockholm County Council and ABC Labs in Sweden developed a multi-panel testing workflow that combined qDBS collected via Capitainer®B with a LC-MS method capable of detecting a panel of 35 analytes in qDBS samples and 37 analytes in liquid urine samples. A total of 99 patients were recruited from a drug dependence clinic in Stockholm and included in the study. When asked for their opinion regarding sample type for drug testing, 97 of the 99 patients included in this study reported a need for an alternative sample type. In summary, this offers a high-throughput method with a short reporting time of less than 24 hours, which is a more useful guide to clinical decision-making than unconfirmed positives from immunoassay screening. In addition, an alternative to supervised urine sampling will increase privacy and dignity for those individuals being tested. Finally, the new method meets forensic standards and can be adapted to meet the evolving requirements within drug and alcohol testing. Read the linked blog article and reach out to us if you want to learn more about alcohol and drug testing solutions via Capitainer sampling.   #toxicology #drugofabuse #drugtesting #toxicologytesting https://lnkd.in/d6yvPsNN